论文部分内容阅读
目的:探讨COX-2反MUC在卵巢上皮癌中的表达及临床意义.方法:应用COX-2的单克降抗体及MUC1的单克降抗体,以SP免疫组织化学方法。对39例卵巢上皮癌.11例良性卵巢上皮癌和10例正常卵巢组织的石蜡标本作COX-2及 MUCl的检测,并分析卵巢上皮癌的临床病理资料.结果:①正常卵巢组织COX-2及MUCl均呈阴性表达,良性卵巢上皮瘤COX-2呈阴性表达,MUCI呈阳性表达.卵巢上皮癌中可有COX-2及MUCl表达,COX-2在正常卵巢.卵巢良性肿瘤与卵巢恶性肿瘤之间三者的表达有极显著差异(P<0.01);MUCl在正常卵巢.卵巢良性,恶性肿瘤之间二者的表达有极显著差异(P<0.01):卵巢上皮癌与卵巢上皮瘤相比二者的表达呈升高趋势,但不具有统计学意义(P>0.05);②COX-2的阳性表达与卵巢上皮癌的临床分期、组织分化程度及病理类型无关(P>0.05):MUCl的阳性表达与卵巢上皮癌的临床分期、组织分化程度及病理类型有关(P<0.05);③COX-2及MUCl的阳性表达与卵巢上皮癌的预后有关(P<0.05);结论:COX-2及MUCl可能是卵巢上皮癌发生的相关基因,与肿瘤的发展及转移有关.检测COX-2及MOCl可以估计卵巢上皮癌患者的预后,辅助指导临床化疗.
Objective: To investigate the expression of COX-2 anti-MUC in epithelial ovarian cancer and its clinical significance.Methods: Monoclonal anti-COX-2 monoclonal antibody and MUC1 monoclonal antibody were used in this study. The COX-2 and MUC1 were detected in 39 cases of epithelial ovarian cancer, 11 cases of benign ovarian epithelial carcinoma and 10 cases of normal ovarian tissue, and the clinicopathological data of ovarian epithelial carcinoma were analyzed.Results: ① The expression of COX-2 And MUC1 were negative expression of COX-2 was positive in benign ovarian epithelial tumors, MUCI was positive expression of epithelial ovarian cancer COX-2 and MUCl expression, COX-2 in normal ovarian benign ovarian cancer and ovarian cancer (P <0.01). There was a significant difference in the expression of MUC1 in normal ovary, benign ovarian and malignant tumors (P <0.01): the correlation between MUC1 expression and ovarian epithelial tumor (P> 0.05). ②The positive expression of COX-2 was not related to the clinical stage, histological differentiation and pathological type of epithelial ovarian cancer (P> 0.05): MUCl (P <0.05); ③The positive expression of COX-2 and MUCl was correlated with the prognosis of epithelial ovarian cancer (P0.05); Conclusion: The expression of COX-2 And MUCl may be related gene in ovarian epithelial carcinogenesis, with the development of tumors Metastasis. MOCl COX-2 protein and can estimate the prognosis of epithelial ovarian cancer patients, the auxiliary clinical chemotherapy.